The estimated Net Worth of Stuart Walter Peltz is at least $24.7 Milion dollars as of 31 January 2023. Stuart Peltz owns over 2,621 units of PTC Therapeutics Inc stock worth over $1,771,720 and over the last 11 years he sold PTCT stock worth over $15,179,531. In addition, he makes $7,759,440 as Chief Executive Officer i Director at PTC Therapeutics Inc.
Stuart has made over 36 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,621 units of PTCT stock worth $119,596 on 31 January 2023.
The largest trade he's ever made was exercising 348,417 units of PTC Therapeutics Inc stock on 7 December 2020 worth over $7,895,129. On average, Stuart trades about 34,031 units every 69 days since 2014. As of 31 January 2023 he still owns at least 54,903 units of PTC Therapeutics Inc stock.
You can see the complete history of Stuart Peltz stock trades at the bottom of the page.
Dr. Stuart W. Peltz Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Peltz is a co-founder of PTC Therapeutics, Inc., and has served as our Chief Executive Officer and a member of our Board since our inception in 1998. He also serves as a director of PTC Therapeutics International Limited, our international headquarters and indirect wholly-owned subsidiary, and as a director of one of our international subsidiary boards. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz previously served as a board member of the BioNJ Board of Trustees from 2005 to 2017, including as its Chairman from 2014 to 2016. Dr. Peltz has received a number of business and scientific awards, including election as a Fellow of the American Academy for the Advancement of Science in 2010, recipient of the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014 and recognition as PharmaVoice's 100 Most Inspiring People in 2009. He served as a member of he board of directors for the Biotechnology Industry Organization (BIO) from 2010 to 2015, including being on BIO's Emerging Companies Section Governing Board. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.
As the Chief Executive Officer i Director of PTC Therapeutics Inc, the total compensation of Stuart Peltz at PTC Therapeutics Inc is $7,759,440. There are no executives at PTC Therapeutics Inc getting paid more.
Stuart Peltz is 60, he's been the Chief Executive Officer i Director of PTC Therapeutics Inc since 1998. There are 7 older and 10 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
Stuart's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel oraz Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: